US

JDRF T1D Fund appoints Ellias as managing director

The JDRF T1D Fund, a venture philanthropy fund focused on type 1 diabetes, has named Katie Ellias as managing director. Previously, Ellias worked at Endeavour Vision where she was a senior investment director.

Venminder rakes in $5 mln Series B

Elizabethtown, Kentucky-based Venminder, the financial services industry’s solution for third party risk management, has secured $5 million in Series B follow-on financing. MissionOG led the round with participation from other investors that included Bain Capital Ventures.

Custom framing firm Framebridge nets $30 mln Series C

Washington, D.C.-based Framebridge, a direct-to-consumer custom framing company, has secured $30 million in Series C funding, according to a blog post. T. Rowe Price led the round.

Service Fusion pulls in $10 mln Series A

Texas-based Service Fusion, a field service management software provider, has secured $10 million in Series A funding. The investor was Five Elms Capital.

Lygos takes in $15.5 mln Series B

Lygos Inc, a creator of new biology based products, has raised $15.5 million in Series B financing. IA Ventures and First Round Capital led the round with participation from Y Combinator Continuity Fund and OS Fund.

VC-backed Crinetics Pharmaceuticals debuts IPO

San Diego-based Crinetics Pharmaceuticals, a drug developer focused on rare endocrine diseases and endocrine-related tumors, has raised $102 million for its IPO after pricing its 6 million shares at $17 per share. The stock began trading July 18, 2018 on the NASDAQ under the ticker symbol "CRNX." J.P. Morgan Securities LLC, Leerink Partners LLC and Piper Jaffray & Co are the lead underwriters. Crinetics' pre-IPO backers include Versant Ventures, 5AM Ventures and Vivo Capital.

Openpath attracts $20 mln Series B

Los Angeles-based Openpath, a provider of smart, secure access systems for the modern office, has raised $20 million in Series B funding. Emergence Capital led the round.

Primary care app K Health inks $12.5 mln

New York-based K Health, a primary care app, has raised $12.5 million in financing. The investors were Mangrove Capital Partners, Lerer Hippeau, Primary Venture Partners, BoxGroup, Max Ventures, Bessemer Venture Partners and Comcast Ventures.

Rubius Therapeutics goes public

Cambridge, Massachusetts-based Rubius Therapeutics, a creator of cellular therapies, has debuted its IPO after pricing its over 10.4 million shares at $23 per share. The stock began trading July 18, 2018 on the NASDAQ under the ticker symbol "RUBY." J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners are the lead underwriters. Rubius' pre-IPO backers include Flagship Pioneering.

Children's media brand Pocket.watch nabs $15 mln Series B

Culver City, California-based Pocket.watch, a children's media brand, has secured $15 million Series B funding. Viacom led the round with participation from other investors that included Greycroft and UTA Ventures.